- AbbVie (NYSE:ABBV -0.9%) submits a supplemental New Drug Application (sNDA) to the FDA seeking approval of the use of IMBRUVICA (ibrutinib) for the treatment of patients with marginal zone lymphoma, a slow-growing form of non-Hodgkin's lymphoma. If approved, it will be the fifth blood cancer indication for the drug.